Usona Institute has been organized to operate exclusively for charitable, scientific, and educational purposes, including, but not limited to, conducting and supporting medical, scientific, and social science research and education on medicines and practices to relieve mental and physical suffering and to improve the quality of life and management of health care through the application of treatments using safe and effective products, including those derived from plants and related materials. In addition, the institute qualifies as a "medical research organization" under section 170(b)(1)(a)(III), as it has a principal purpose of conducting medical research and will be primarily engaged in medical research in conjunction with university of Wisconsin hospitals and clinics.
Largest programs · fiscal year 2025
Psil301 studyusona institute is conducting a phase 3 clinical trial, "a phase 3, randomized, double-blind, multicenter study to evaluate the efficacy, safety, and tolerability of psilocybin in adults with major depressive disorder (mdd)," also known as the uaspire trial. This research seeks to investigate the potential benefits and safety of psilocybin as a treatment option for individuals with ma… Read more
Psil301 studyusona institute is conducting a phase 3 clinical trial, "a phase 3, randomized, double-blind, multicenter study to evaluate the efficacy, safety, and tolerability of psilocybin in adults with major depressive disorder (mdd)," also known as the uaspire trial. This research seeks to investigate the potential benefits and safety of psilocybin as a treatment option for individuals with major depressive disorder as quickly and safely as possible.2025 accomplishmentsfull enrollment and randomization achieved. On November 13, 2025, usona completed enrollment and randomization for the uaspire psil301 phase 3 trial, reaching 238 participants randomized across 30 clinical sites throughout the united states, including Veterans Affairs (va) facilities and academic medical centers. This milestone marks a pivotal step toward nda submission and potential fda approval of psilocybin for mdd.nda preparation and fda engagement. Usona advanced nda readiness across multiple modules in 2025. Cmc module 3 completed a six-month cross-functional drafting and review process. Regulatory affairs received updated alignment correspondence with fda on rolling submission expectations. Facilitator training and psychosocial support. A total of 178 facilitators were trained across all psil301 sites. Usona updated the clinical facilitator manual to version 4.0, developed a new sponsor oversight plan for facilitation activities, and launched a retention-focused site training based on best practices from high-performing sites.participant retention. An irb-approved participant retention program was implemented to support participant engagement through week 58 of follow-up as participants transition into the long-term follow-up phase.quality system and inspection readiness. Pre-approval inspection (pai) readiness activities were initiated with contract manufacturing organizations.longer-term goal. Usona's objective is to complete nda submission to the fda and secure approval of psilocybin as a safe and effective treatment for mdd made broadly and affordably accessible without patent restrictions or commercial exclusivity.
$33,989,315 spent · 93.4% of program spending
5-Meo-dmt phase 2 studyusona institute is developing 5-meo-dmt as a potential treatment for post-traumatic stress disorder (PTSD) in adults through a planned two-part (phase 2a/2b) clinical trial (meo201). Part a (phase 2a) is designed to obtain safety data and effect size estimates in a PTSD patient population to optimize the part b (phase 2b) design, which will evaluate the safety and efficacy o… Read more
5-Meo-dmt phase 2 studyusona institute is developing 5-meo-dmt as a potential treatment for post-traumatic stress disorder (PTSD) in adults through a planned two-part (phase 2a/2b) clinical trial (meo201). Part a (phase 2a) is designed to obtain safety data and effect size estimates in a PTSD patient population to optimize the part b (phase 2b) design, which will evaluate the safety and efficacy of the selected 5-meo-dmt regimen.2025 accomplishmentsprotocol development finalized. The meo201 protocol synopsis was completed and finalized following external review by subject matter experts and internal cross-functional review, establishing the scientific and operational foundation for the planned phase 2 trial.cro selection process conducted. Usona evaluated proposals from multiple contract research organizations and conducted competitive bid-defense meetings to identify a qualified cro partner for meo201, building organizational readiness for future clinical trial operations.gmp drug product manufactured. Gmp manufacturing of the 5-meo-dmt phase 2a drug product both active and placebo was successfully completed. All associated analytical method validations and release testing were finalized.nonclinical studies advanced generating key pharmacokinetic data to inform future regulatory submissions.strategic prioritization decision. Following completion of these foundational activities, usona's leadership determined that clinical trial initiation for meo201 would be deferred to prioritize resources toward completing the psil301 phase 3 program and advancing the psilocybin nda submission. Preparatory work completed in 2025 positions the 5-meo program for future clinical activation.longer-term goal. Usona's objective is to evaluate 5-meo-dmt as a safe and effective treatment for PTSD through a rigorous phase 2 clinical program, ultimately generating the data needed to support a potential phase 3 pathway and regulatory approval providing patients with a non-proprietary treatment option.
$1,543,663 spent · 4.2% of program spending
Events & programsusona's education programs are intentionally designed to provide immersive and interactive learning experiences. These programs focus on preparing clinical, scientific, and academic leaders with the critical knowledge needed to advance psychedelic therapy in clinical research and preparation for future delivery of care, upon approval. Through a carefully tailored curriculum, diver… Read more
Events & programsusona's education programs are intentionally designed to provide immersive and interactive learning experiences. These programs focus on preparing clinical, scientific, and academic leaders with the critical knowledge needed to advance psychedelic therapy in clinical research and preparation for future delivery of care, upon approval. Through a carefully tailored curriculum, diverse faculty, experientials, and guest speakers, participants gain the expertise and foundational knowledge required to pave the way for best practices in future care delivery models. 2025 Accomplishmentshosted over 200 attendees across usona-led events at the campus in 2025, broadening usona's impact in psychedelic therapy education. Delivered curriculum and immersive programs designed to prepare scientific, clinical, and academic leaders. Awarded full and partial scholarships for participation in usona's education programs, expanding access and diversity of participants. Strengthened partnerships with academic institutions and healthcare organizations to prepare practitioners and systems for future delivery of psychedelic-assisted care.
$857,225 spent · 2.4% of program spending
Where each dollar went · fiscal year 2025
Of every dollar it spent, 94¢ went to programs, 6¢ to management and 0¢ to fundraising.
Programs $36,390,203
Management $2,136,831
Fundraising $0
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
94%
Meets
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$35,851,828Fiscal year 2025
Expenses$38,527,034Fiscal year 2025
Total assets$98,365,654Fiscal year 2025
Total liabilities$55,309,227Fiscal year 2025
Fiscal year ending December2025
Revenue$35,851,828
Expenses$38,527,034
Net income−$2,675,206
Net assets$43,056,427
Notable sources of revenue
Percent of total revenue
Contributions
$35,405,819
98.8%
Program services
$126,182
0.4%
Investment income
$51,534
0.1%
Other (net)
$268,293
0.7%
Assets / debt
Total assets
$98,365,654
Total liabilities
$55,309,227
Net assets
$43,056,427
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$54,880,999
Expenses$17,293,190
Net income$37,587,809
Net assets$71,120,083
Notable sources of revenue
Percent of total revenue
Contributions
$53,766,608
98.0%
Program services
$76,753
0.1%
Investment income
$564,774
1.0%
Other (net)
$472,864
0.9%
Assets / debt
Total assets
$180,248,504
Total liabilities
$109,128,421
Net assets
$71,120,083
Compensation
Not in our extract for this year.
Fiscal year ending December2022
Revenue$21,184,086
Expenses$17,065,106
Net income$4,118,980
Net assets$33,570,999
Notable sources of revenue
Percent of total revenue
Contributions
$22,001,698
103.9%
Program services
$41,850
0.2%
Investment income
$31,848
0.2%
Other (net)
−$891,310
−4.2%
Assets / debt
Total assets
$71,860,814
Total liabilities
$38,289,815
Net assets
$33,570,999
Compensation
Officers and key employees
$36,000
Share of expenses
0.2%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?